NCT02661971View on ClinicalTrials.gov

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

June 20, 2022

Conditions
Stomach CancerGastroesophageal Junction Cancer
Interventions
DRUG

Docetaxel

Docetaxel 50 mg/m², d1

DRUG

Oxaliplatin

Oxaliplatin 85 mg/m², d1

DRUG

Calciumfolinat

Leucovorin 200 mg/m², d1

DRUG

5-Fluorouracil

5-FU 2600 mg/m², d1

BIOLOGICAL

Ramucirumab

Ramucirumab 8mg/kg, d1

Trial Locations (2)

60488

Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt

Unknown

"Università degli studi della Campania Luigi Vanvitelli", Napoli

All Listed Sponsors
lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT02661971 - FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) | Biotech Hunter | Biotech Hunter